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1. Introduction 
The glyoxalase system contains two enzymes. 
Glyoxalase I requires glutathione (GSH) as coenzyme 
and catalyses the disproportionation of methylglyoxal 
into the thiol ester of GSH and lactic acid. Glyoxalase 
II then hydrolyses this ester to free GSH and lactate 
PI. 
There have been suggestions that the ubiquitous 
[2] glyoxalase enzyme system may aid in cell growth 
regulation by controlling the level of methylglyoxal 
[2-41. Indeed, the proposal [3,5 ] that selective 
inhibition of glyoxalase I may provide carcinostatic 
activity by preventing metabolism of cw-ketoaldehydes 
in tumour cells has considerable experimental support. 
The carcinostatic activity of a-ketoaldehydes [6] is 
well-known, but their chemotherapeutic use is 
obviated by rapid metabolism to cw-hydroxyacids (by 
the glyoxalase system). 
Based on the above, approaches to antineoplastic 
agents have included preparation and screening of 
substituted-glutathione analogues [5,7,8]. For 
example, & GSR (R = -(CH& CO.Ar, -CHsAr, 
-(CHs), H) are powerful competitive inhibitors of 
glyoxalase I, [3,9,10] and are cytotoxic to L1210 
leukaemia and KB cells in tissue culture [5]. In addi- 
tion, several S- and N- substituted cysteinylglycines 
have been evaluated as glyoxalase inhibitors [8]. 
However, rapid metabolism rendered such compounds 
inactive in vivo [7,8,11] and attempts have been 
made to find degradation-resistant versions [7,8]. 
o-Hydroxythiolesters (product-like inhibitors) have 
no significant antileukaemic activity [ 121. 
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Another inhibitor of glyoxalase I, (2) was isolated 
from Streptomyces gniseosporeus. This inhibits 
glyoxalase I if incubated with GSH, presumably by 
conversion to 3. Compound 2 showed strong inhibi- 
tion of growth of HeLa cells and Ehrlich ascites 
carcinoma, weak inhibition of solid type Ehrlich 
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carcinoma and prolonged the survival period of L12 lo- 
inoculated mice [13,14]. Another compound (MS-3), 
from a mushroom, inhibits glyoxalase I and growth of 
Yoshida rat sarcoma cells in cell culture [ 15 J. Reduc- 
tones (e.g., ascorbate) suppress the growth of 
Sarcoma 180 and are also effective glyoxalase inhib- 
itors, suggested to be because of their structural 
similarity to methylglyoxal [ 161. 
We report here several new inhibitors of glyoxalase I, 
designed on transition-state analogy as a new approach 
to potential antileukaemic agents. 
2. Materials and methods 
Malt01 (3-hydroxy-2-methyl-4H-pyran-4-one), 
rhodizonic acid and 2,3-dihydroxybenzoic acid were 
from Aldrich. Squaric acid, dihydroxyfumaric acid, 
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gluconod-lactone, D-isoascorbic acid, glutathione, 
methyiglyoxal and glyoxalase I (grade IV, yeast) were 
from Sigma. Enzyme assays were performed (25’C, 
0.05 M phosphate buffer (pH 6.6)) using a thermo- 
statted Pye-Unicam SP8-100 spectrophotometer. Solu- 
tions were prepared, on the day of the assays, using 
distilled, deionized water. Stock inhibitor solutions 
were prepared in the above buffer and adjusted, when 
necessary, to pH 6.6. Methyiglyoxal, GSH and buffer 
(and inhibitor) were added to a cuvette and allowed 
to stand for 5 min in the thermostatted compartment 
of the spectrophotometer o allow complete hemimer- 
captal equilibration. Sufficient glyoxalase I solution, 
in the presence of 0.1% bovine serum albumin (Sigma) 
as a stabilising agent 1201, was added to give an easily 
measured initial rate (fo~owed at 240 nm). Hemimer- 
captal substrate concentrations were calculated from 
the concentrations of GSH and methylglyoxal added, 
using a value of 3.1 X low3 M for the dissociation 
constant [9] of the hemimercaptal tpH 6.6. Data 
were analysed using an Exidy Sorcerer Minicomputer 
(Z80 chip); we are grateful to Mr John Torkington for 
programming assistance. 
3. Results 
Figure 1 and table 1 show that malt01 is an effec- 
tive inhibitor of glyoxalase I at pH 6.6. From an 
Eadie plot of I’, versus v,/[hemimercaptal], the app. 
Km for the hemimercaptal substrate is3.0 X 10e4 M 
(i 1.6 X 10e4 M) assuming both enantiomers are 
bound productively. This value agrees well with pub- 
lished values 18,171. Lineweaver-Burk (l/V, versus 
11 ~hemimercaptal]), analysis at various inhibitor con- 
centrations indicated non-competitive inhibition 
(using the terminology of Cleland [ 181); however, the 
replot of the intercepts against inhibitor concentra- 
tion may be curved (see fig.le). The Dixon plot, of 
l/V, versus [maltol] (in fig.1) yields 3.94 X low4 M 
for Kl and, again, the pattern is that of non-compe- 
titive inhibition. This value of K, was calculated as 
the average value of the intercepts on the [maltol] 
axis, values of which lay between 3.8 1 and 4.00 X 
10m4 M (4 determinations). 
Other inhibitors are collected in table 1; dissection 
of the inhibition kinetics has not yet been carried out 
for them, but it is apparent that some of these simple 
compounds are rather effective inhibitors. 
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Fig.1. Dixon plot of f/PO versus [maltolf at various con- 
centrations of hemimercaptal substrate for glyoxalase I at 
pH 6.6. Initial concentrations of hemimercaptal were (a) 
2.51 X 1O-4 M; (b) 1.76 X 1O-4 M;(c) 1.07 x 1O-4 M;(d) 
7.76 X IO-’ M. Line (e) represents a replot of the intercepts 
(l/V, axis) from a Lineweaver-Burk plot (l/V0 versus l/So) 
of the same data. Points are experimental: lines were obtained 
by linear least squares regression analysis of the data: it is 
possible that line (e) is actually curvilinear. The value of jYi, 
obtained from the common intersection on the Imaltol] axis 
is 3.94 X IO-” M (see text). 
4, Discussion 
The effective inhibition of yeast glyoxalase I by a 
molecule as simple as malt01 is surprising, especially 
in view of the rather low Ki (-4 X low4 M), compa- 
rable with the Km value. Most other i~ibitors with 
comparable Kj values are derivatives of ~uta~o~e or 
cysteinylglycine. However, a group of reductones has 
recently been reported as glyoxalase I inhibitors, 
although detailed inhibition studies or inhibition con- 
stants were not published [161. Particularly effective 
was ascorbic acid. The structural feature common to 
the reductones was I?j the enediol (or part of it). The 
compounds of table 1 were selected on the basis of 
their resemblance to a putative nediol intermediate. 
HO 1 x Ho I 
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Table 1 
Inhibitors of yeast glyoxalase I (pH 6.6,25”(Z) 
Compound Cont. (mM) % inhibition 
0 
HO 
‘d, 
0, D-isoascorbate 
HO 
H0.CH.CH20H 
HO 
squaric acid 
HO 
0 
HO 
rhodizonic acid 
HO 
0 
HO 
HO 
COPH 
dihydroxy-fumaric 
acid 
COzH 
COPH 
OH 
2,3-dihydroxy- 
benzoic acid 
OH 
0.40 50 
10.00 
0.25 
1.00 
10.00 
100 
70 
50.4 
50 
0.583 72 
CHzOH 
10.00 9 
OH 
The concentration of hemimercaptal substrate was 2.51 X 10s4 M 
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The glyoxalase inhibitor from Streptomyces griseo- 
sporeus, 2,2-crotonyloxymethyl-4,5,6-trihydroxy- 
cyclohex-2-enone [13,14], contains structural unit 5, 
very close to 4_ but non-coplanar. Malt01 contains the 
analogous element 6 coplanar by virtue of the sp’ 
hybridised carbon to which the -OH group is attached; 
the other compounds in table 1 also contain either 
an enediol or a paene-enediol structure. 
Until recently, the mechanism of action of 
glyoxalase I was believed to be an example of an 
intramolecular hydride shift [19]. However, the 
observation (by NMR) of incorporation of solvent 
protons is consistent with a mechanism involving an 
enediol [ 201 form of the substrate, possibly chelated 
to Mg2’ at the active-site (eq. (1)) [21]. 
II H-Y-oH 
H-C-OH+ C - 
AH 
y=O (1) 
SC SC 
7H3 CH3 OH? 
c=o ‘c/ 
: : I 
CH3 
’ 
Inhibition by some of the compounds in table 1 
(as well as by the reductones and crotonate,?) 
could be ascribed to simple similarity of the inhibitor 
to the substrate (hemimercaptal) structure in the 
Michaelis complex (i.e., before significant progress 
along the reaction coordinate has occurred), as 
suggested for the reductones [16]. However, it is 
possible that these inhibitors are mimicking to some 
extent, some of the binding features distinctive of the 
transition-state (presumably physically and energeti- 
cally approximate to the enediol intermediate). The 
concept of ‘transition-state analogues’ has led to some 
powerful enzyme inhibitors [22]. The lack of copla- 
narity of the structural element, 5 found in D-gluconic- 
S-lactone may explain its relatively low inhibitory 
effect. More detailed study is required to distinguish 
transition-state from ground state (Michaelis-complex) 
analogy. 
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